High-grade prostate cancer in the prostate cancer prevention trial: Fact or artifact?

Journal of the National Cancer Institute

Volumn 99, Issue 18, 2007, Pages 1355-1356

  Andriole, Gerald L ^a   Humphrey, Peter A ^a   Serfling, Robert J ^b   Grubb, Robert L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ARTIFACT; CANCER INCIDENCE; CANCER PREVENTION; EDITORIAL; HISTOPATHOLOGY; HUMAN; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; AGED; EPIDEMIOLOGY; HOSPITALIZATION; INCIDENCE; MALE; MIDDLE AGED; NEEDLE BIOPSY; NOTE; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; ANTICARCINOGENIC AGENTS; BIAS (EPIDEMIOLOGY); BIOPSY, NEEDLE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34748902902     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djm151     Document Type: Editorial

References (16)

1. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
2. Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, et al. Effect of dual 5 alpha-reductase inhibitor on markers of tumor regression in prostate cancer. J Urol 2004;172:915-9.
3. Thorpe JF, Jain S, Marczylo TH, Gescher AJ, Steward WP, Mellon JK. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 2007;89:207-11.
4. de Vere White RW. Finasteride for chemoprevention of prostate cancer: why has it not been embraced? J Clin Oncol 2007;25:2999-3000.
5. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83.
6. Reuter VE. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 1997;49 (Suppl):16-22.
7. Petraki CD, Sfikas CP. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol 2007;22:107-18.
8. Civantos F, Soloway MS, Pinto JE. Histopathological effects of androgen deprivation in prostatic cancer. Semin Urol Oncol 1996;14(Suppl 2):22-31.
9. Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bonnow J, et al. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology 1999;53:696-700.
10. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, Gann PH. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74.
11. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, et al. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006;175:505-9.
12. Serfling R, Shulman M, Thompson GL, Xiao Z, Benaim E, Roehrborn CG, et al. Quantifying the impact of prostate volumes, number of biopsy cores and 5α-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. J Urol 2007;177:2352-6.
13. Kibel AS. Optimizing prostate biopsy techniques. J Urol 2007;177:1976-7.
14. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, et al. Clinical and pathological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-91.
15. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma . Proc Natl Acad Sci USA 2006;103:10991-6.
16. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 2004;172 (Pt 1):1314-7.